

**2ND AND 3RD LINE TREATMENT FOR HER2-POSITIVE METASTATIC BREAST CANCER
TOTAL PRESCRIPTIONS
U.S. UNITS BY PRODUCT, INCLUDING
Q4 2012 – Q3 2014**

	2012	2013			
	Q4	Q1	Q2	Q3	Q4
Ixemptra®	55	56	60	28	53
Kadcyla® ²	0	14	145	257	314
Perjeta®	140	180	214	187	217
Tykerb®	6,059	5,336	4,494	4,000	3,831
Xeloda®	72,329	66,830	67,966	68,381	68,170
Total	78,583	72,416	72,879	72,853	72,585
Ixemptra®	0.1%	0.1%	0.1%	0.0%	0.1%
Kadcyla®		0.0%	0.2%	0.4%	0.4%
Perjeta®	0.2%	0.2%	0.3%	0.3%	0.3%
Tykerb®	7.7%	7.4%	6.2%	5.5%	5.3%
Xeloda®	92.0%	92.3%	93.3%	93.9%	93.9%
Total	100.0%	100.0%	100.0%	100.0%	100.0%

Notes & Sources:

¹ Excludes Herceptin®.

² Annual Kadcyla® prescriptions totaled 730 in 2013.

Kadcyla® is indicated as a single agent for the treatment of people with HER2-positive metastatic breast cancer with chemotherapy. See, e.g., Exhibit 2317. In contrast:

Xeloda® can be used to treat colon, rectal, and other cancers. See, e.g., Exhibit 2246.

Perjeta® received FDA approval for neoadjuvant breast cancer therapy. See, e.g., Exhibit 2211.

Tykerb® is used to treat breast cancer, but is prescribed with a second medicine (Xeloda® or Femara®). See, e.g., Exhibit 2218. (These assertions and sources can be found in the report.)

Includes brand and generic values.

Ixemptra® includes brand IXEMPRA 10/2007 BMO, identified in field 'Product.'

Kadcyla® includes brand KADCYLA 02/2013 GTC, identified in field 'Product.'

Perjeta® includes brand PERJETA 06/2012 GTC, identified in field 'Product.'

Tykerb® includes brand TYKERB 03/2007 GSK, identified in field 'Product.'

Xeloda® includes brand XELODA 05/1998 GTC, identified in field 'Product,' and generic capecitabine, identified in field 'Product.'

Includes Xeloda® (capecitabine), which is indicated for use with Tykerb® (lapatinib) in second-line therapy. Excludes capecitabine, which is indicated for the use of other cancers. See Exhibit 2218 and Exhibit 2343.

Values reflect field 'TRx'.

Percentage calculated as percent of quarterly total.

Products identified from Exhibit 2103 and Exhibit 2224.

Data from IMS Health.